USPSTF Recommends Osteoporosis Screening for Women Aged 65 Years and Older
By Elana Gotkine HealthDay Reporter
TUESDAY, June 11, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis for women aged 65 years and older and for postmenopausal women younger than 65 years with one or more risk factors. These recommendations form the basis of a draft recommendation statement published online June 11.
Researchers reviewed the evidence from 138 studies reporting trials or systematic reviews that assessed the benefits or harms of screening in adults without known osteoporosis or medical conditions associated with bone metabolism compared with no screening or usual care. Three randomized controlled trials and two systematic reviews reported on the direct benefits of screening in European women (median age, 71 to 76 years). The researchers found that screening was associated with a reduced risk for hip fractures and major osteoporotic fractures compared with usual care across trials (pooled relative risks, 0.83 and 0.94, respectively). The corresponding absolute risk differences were five and six fewer fractures per 1,000 participants.
Based on these findings the USPSTF recommends osteoporosis screening to prevent osteoporotic fractures in women aged 65 years or older (B recommendation). For postmenopausal women younger than 65 years with one or more risk factors for osteoporosis, screening is recommended to prevent osteoporotic fractures (B recommendation). For men, the current evidence is insufficient for assessing the balance of benefits and harms of screening to prevent osteoporotic fractures (I statement).
The draft recommendation statement and draft evidence review have been posted for public comment. Comments can be submitted from June 11 to July 8, 2024.
Draft Recommendation Statement
Comment on Recommendation Statement
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.